An Open-Label, Multi-Centre, Extension Study, evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens in Patients with Prostate Cancer. -

• Conditions: Prostate cancer patient; MedDRA version: 7.0Level: pr tClassification code 10060862

• Registration Number: EUCTR2005-004943-72-DE
• Lead Sponsor: Ferring Pharmaceuticals A/S

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01-20
• Last Update Posted: 21 January 2013

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Male
• Target Recruitment: 425

Inclusion Criteria

Has completed the CS15 study
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Has been withdrawn from the FE200486 CS15 study

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified